Navigation Links
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Date:3/13/2009

ror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a r
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
2. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
4. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
5. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
8. Eiger BioPharmaceuticals Raises $7.1 Million A Round
9. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
10. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
11. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... GliaCure, a privately-held biotechnology company focused ... and neuropsychiatric disorders based on glial targets, announced ... in a Phase 1b clinical trial of its ... a potential disease-modifying treatment. GliaCure,s innovative approach to ... both promotes the clearance of amyloid and stimulates ...
(Date:5/4/2015)... , May 4, 2015  Tikcro Technologies Ltd. ... annual report on Form 20-F for the fiscal year ... Exchange Commission ("SEC"). The annual report on Form 20-F ... of antibodies in the area of cancer immune checkpoints. ... qualities of high specificity and binding in targeting certain ...
(Date:5/4/2015)... 2015  Traverse Biosciences announced today that it ... agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... for the treatment and control of periodontal disease ... Biosciences has also granted Aratana an exclusive option ... of periodontal disease in companion animals, inclusive of ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... Calif., March 31 Sigma-Aldrich (Nasdaq: ... high quality services and oligonucleotides to Gene Oracle, an ... the agreement, Sigma-Aldrich will be the exclusive supplier of ... will engage in co-marketing efforts to promote the GeneIOS ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... the company,s board of directors. Dr. Hutson retired ... in various research and leadership positions with that company, ... Research and Development and director of Pfizer,s pharmaceutical R&D ...
... MYL ) today announced that Matrix Laboratories ... 71.2% controlling interest, has received the first tentative approval ... the President,s Emergency Plan for AIDS Relief (PEPFAR) for ... Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.Mylan Vice Chairman ...
Cached Biology Technology:Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 2Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 4Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... German . To further enhance ... Forschungsgemeinschaft (DFG, German Research Foundation) has established twelve new ... DFG,s relevant Grants Committee in Bonn. The new Research ... training at a highly specialised level within a structured ...
... can incite the body to attack its own nerve ... both viral and nerve proteins. The dual-receptor observation suggests ... be triggered in susceptible young adults afflicted with multiple ... Immunology scientists Qingyong "John" Ji, Antoine Perchellet, and Joan ...
... University of Illinois at Chicago have discovered that an ... down and inhibiting the formation of excess scar tissue ... this week in Nature Cell Biology . ... "recruited" to the wound site that rapidly produce extracellular ...
Cached Biology News:DFG establishes 12 new research training groups 2DFG establishes 12 new research training groups 3DFG establishes 12 new research training groups 4DFG establishes 12 new research training groups 5DFG establishes 12 new research training groups 6Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 2Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 3Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 4Researchers discover mechanism that limits scar formation 2
Request Info...
... The Luminex® 200 System with ... for developing single and multi-analyte assays ... contains the new, powerful user friendly ... user can design specific templates for ...
Recombinant Rat Leptin, CF...
... culture chambered coverslips are convenient ... staining and imaging. The chambered ... with standard optical-quality coverslips and ... to use. Preassembled CultureWell systems ...
Biology Products: